all ( 12 results found)
EpiPen® Healthcare Professional Letter
EpiPen® Healthcare Professional Letter
Fluoroquinolones DHPC_HPRA_FINAL vs2 30-05-23
Gavreto DHPC dated 16 Jun 2023
IMBRUVICA® (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
Topamax: Ongoing EU review of potential risk of neurodevelopmental disorders in children exposed in utero
Zolgensma (onasemnogene abeparvovec): Important Safety Information